Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies
Authors:
- 1 June 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (6) , 1488-1493
Abstract
The accumulation of data through a prospective, multicenter coordinated registry network is a practical way to gather real world evidence on the performance of novel prostate ablation technologies. Urological oncologists, targeted biopsy experts, industry representatives and representatives of the FDA (Food and Drug Administration) convened to discuss the role, feasibility and important data elements of a coordinated registry network to assess new and existing prostate ablation technologies. A multiround Delphi consensus approach was performed which included the opinion of 15 expert urologists, representatives of the FDA and leadership from high intensity focused ultrasound device manufacturers. Stakeholders provided input in 3 consecutive rounds with conference calls following each round to obtain consensus on remaining items. Participants agreed that these elements initially developed for high intensity focused ultrasound are compatible with other prostate ablation technologies. Coordinated registry network elements were reviewed and supplemented with data elements from the FDA common study metrics. The working group reached consensus on capturing specific patient demographics, treatment details, oncologic outcomes, functional outcomes and complications. Validated health related quality of life questionnaires were selected to capture patient reported outcomes, including the IIEF-5 (International Index of Erectile Function-5), the I-PSS (International Prostate Symptom Score), the EPIC-26 (Expanded Prostate Cancer Index Composite-26) and the MSHQ-EjD (Male Sexual Health Questionnaire for Ejaculatory Dysfunction). Group consensus was to obtain followup multiparametric magnetic resonance imaging and prostate biopsy approximately 12 months after ablation with additional imaging or biopsy performed as clinically indicated. A national prostate ablation coordinated registry network brings forth vital practice pattern and outcomes data for this emerging treatment paradigm in the United States. Our multiple stakeholder consensus identifies critical elements to evaluate new and existing energy modalities and devices.Keywords
This publication has 17 references indexed in Scilit:
- PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2European Urology, 2016
- Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development StudyEuropean Urology, 2015
- Bridging Unmet Medical Device Ecosystem Needs With Strategically Coordinated Registries NetworksJAMA, 2015
- Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus projectWorld Journal of Urology, 2015
- Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial DesignEuropean Urology, 2014
- Role of multiparametric magnetic resonance imaging ( MRI ) in focal therapy for prostate cancer: a D elphi consensus projectBJU International, 2013
- 979 Localized prostate cancer control with primary HIFU therapy: Outcomes from 5663 men followed with the @-registryEuropean Urology Supplements, 2012
- Development and Validation of an Abbreviated Version of the Expanded Prostate Cancer Index Composite Instrument for Measuring Health-related Quality of Life Among Prostate Cancer SurvivorsUrology, 2010
- Development and Validation of Four-Item Version of Male Sexual Health Questionnaire to Assess Ejaculatory DysfunctionUrology, 2007
- Classification of Surgical ComplicationsAnnals of Surgery, 2004